Laurus Labs Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Laurus Labs Ltd. on BSE

Load latest

Laurus Labs Ltd.

09 Apr 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Laurus Labs Limited-Compliance Certificate For The Half-Year Ended March 31, …

BSE India

In terms of Regulation 7(3) of the Listing Regulations, please find enclosed a Certificate dated April 03, 2019, duly signed by the Authorised Signatory of Karvy Fintech Private Limited, Registrar & Share Transfer Agent and the Company Secretary of the Company for the half-year ended March 31, 2019 confirming compliance of the provisions of Regulation 7(2) of Listing Regulations. This is for your information and records.

pdf

Laurus Labs Ltd.

09 Apr 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Statement Of Investor Complaints For The Quarter Ended March 2019

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- G Venkateswar ReddyDesignation :- Company Secretary and Compliance Officer

Laurus Labs Ltd.

05 Apr 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Shareholding for the Period Ended March 31, 2019

BSE India

Laurus Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here

Laurus Labs Ltd.

04 Apr 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Closure of Trading Window

BSE India

Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and the circular issued by the Stock Exchanges, the trading window for dealing in the shares of the Company shall remain closed from 4th April 2019 till 48 hours after the declaration of financial results for the quarter and year ended 31st March 2019. The date of Board Meeting of the Company for consideration and declaration of the Standalone and Consolidated Financial Results for the quarter and year ended 31st March 2019 will be intimated later. This is for your information and records.

pdf

Laurus Labs Ltd.

29 Mar 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Raju Srihari Kalidindi

pdf

Laurus Labs Ltd.

28 Mar 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amansa Holdings Pvt Ltd

pdf

Laurus Labs Ltd.

26 Mar 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Laurus Labs enters into strategic partnership agreement with the Global Fund Laurus Labs Limited is pleased to announce that the Company has entered into a strategic partnership agreement with Global Fund for a period of 3.5 years. Through this long term agreement Laurus Labs will have the volume commitments from the Global Fund for the treatment of HIV/AIDS. Under this Partnership agreement Laurus Labs received and executed the order from Global Fund which would cater to the supplies of the high burden diseases countries in Sub Saharan African (SSA) region. This is the maiden order for Tenofovir/Lamivudine/Dolutegravir 300/300/50mg (TLD) after the Company received a tentative approval from USFDA in the month of February 2019. A press release to this extent is also attached for your information and records.

pdf

Laurus Labs Ltd.

26 Mar 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Raju Srihari Kalidindi

pdf

Laurus Labs Ltd.

21 Mar 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Laurus Labs intimates Schedule of Analyst/ Institutional Investor Meetings to be conducted on March 25, 2019 and the details are as follows: Date - March 25, 2019 Analyst/Investors - Motilal Osawal-Annual India Ideation Conference 2019 Type of Interaction-One-on-One/Group Meetings Location -Mumbai

pdf

Laurus Labs Ltd.

18 Mar 2019

599.10

0.65%

Corp. Note

Laurus Labs Ltd - 540222 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for FIL Capital Management (Mauritius) Ltd & Fidelity India Principals (acting through its trustee FIL Capital Advisors Trustee Co. Pvt Ltd)

pdf

Is Laurus Labs Ltd. worth buying?

1218 Votes:

Buy 79.56%

Sell 10.84%

Hold 9.61%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf